title: Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside.
abstract: Although the initial characterization of the various MEN-2 associated phenotypes (familial medullary thyroid cancer, multiple endocrine neoplasia 2A and 2B) evolved at the bedside, it was at the bench where the underlying RET (REarranged during Transfection) germline mutations were identified. Molecular information has revolutionized our understanding and continues to transform the clinical management of this fascinating endocrine tumor syndrome of neural crest derivation, which consists of medullary thyroid cancer, pheochromocytoma, and parathyroid hyperplasia/adenoma. DNA-based identification of RET carriers did not require comprehension of the gene, but was a prerequisite for clarifying gene function and devising biologic compounds blocking RET phosphorylation. With the continuing expansion of our knowledge about the underlying molecular mechanisms and our growing therapeutic abilities, multiple endocrine neoplasia type 2 is gradually returning home to the bedside, closing the loop from bedside to bench to bedside.
authors.affiliation: Department of General, Visceral and Vascular Surgery, Martin-Luther-University Halle-Wittenberg, Ernst-Grube-Strasse 40, D-06097 Halle/Saale, Germany. AndreasMachens@aol.com
authors.forename: Andreas
authors.initials: A
authors.lastname: Machens
authors.forename: Henning
authors.initials: H
authors.lastname: Dralle
mesh_terms: D000236:Adenoma / Q000235:genetics / Q000473:pathology; D000310:Adrenal Gland Neoplasms / Q000235:genetics / Q000473:pathology; D000313:Adrenal Medulla / Q000473:pathology; D000367:Age Factors; D000818:Animals; D018276:Carcinoma, Medullary / Q000235:genetics / Q000473:pathology; D005838:Genotype; D018095:Germ-Line Mutation; D006801:Humans; D006965:Hyperplasia; D018813:Multiple Endocrine Neoplasia Type 2a / Q000235:genetics* / Q000473:pathology; D018814:Multiple Endocrine Neoplasia Type 2b / Q000235:genetics / Q000473:pathology; D009432:Neural Crest / Q000473:pathology; D010282:Parathyroid Neoplasms / Q000235:genetics / Q000473:pathology; D010641:Phenotype; D010673:Pheochromocytoma / Q000235:genetics / Q000473:pathology; D051096:Proto-Oncogene Proteins c-ret / Q000235:genetics*; D013577:Syndrome; D013964:Thyroid Neoplasms / Q000235:genetics / Q000473:pathology
chemical_list: D051096:Proto-Oncogene Proteins c-ret